Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
CAL-120 Etoposide
0.0010833
Topo II
Chemotherapy
 1.0065 0.00056
CAL-120 Etoposide
0.0033333
Topo II
Chemotherapy
 0.9503 0.00049
CAL-120 Etoposide
0.01
Topo II
Chemotherapy
 0.9565 0.00489
CAL-120 Etoposide
0.031667
Topo II
Chemotherapy
 0.9554 0.00956
CAL-120 Etoposide
0.1
Topo II
Chemotherapy
 0.8793 0.01678
CAL-120 Etoposide
0.31623
Topo II
Chemotherapy
 0.6698 0.07961
CAL-120 Etoposide
1.0
Topo II
Chemotherapy
 0.2084 0.23737
CAL-120 Etoposide
3.1623
Topo II
Chemotherapy
 -0.0641 0.22073
CAL-120 Etoposide
10.0
Topo II
Chemotherapy
 -0.1663 0.28406
CAL-120 Dasatinib
0.001
BCR/ABL
MAPK/nRTK
 1.0279 -0.00119
CAL-120 Dasatinib
0.0031623
BCR/ABL
MAPK/nRTK
 0.8807 -0.00157
CAL-120 Dasatinib
0.01
BCR/ABL
MAPK/nRTK
 0.8558 0.00027
CAL-120 Dasatinib
0.031623
BCR/ABL
MAPK/nRTK
 0.6812 0.02159
CAL-120 Dasatinib
0.1
BCR/ABL
MAPK/nRTK
 0.2735 0.08799
CAL-120 Dasatinib
0.31623
BCR/ABL
MAPK/nRTK
 0.2605 0.14095
CAL-120 Dasatinib
1.0
BCR/ABL
MAPK/nRTK
 0.1003 0.13866
CAL-120 Dasatinib
3.1623
BCR/ABL
MAPK/nRTK
 0.1763 0.11394
CAL-120 Dasatinib
10.0
BCR/ABL
MAPK/nRTK
 0.2071 0.10399
CAL-120 Trametinib
0.0001
MEK
MAPK/nRTK
 0.9754 -0.00225
CAL-120 Trametinib
0.00031623
MEK
MAPK/nRTK
 0.9557 0.00003
CAL-120 Trametinib
0.001
MEK
MAPK/nRTK
 0.9296 -0.00054
CAL-120 Trametinib
0.0031623
MEK
MAPK/nRTK
 0.9070 0.00535
CAL-120 Trametinib
0.01
MEK
MAPK/nRTK
 0.7597 0.01325
CAL-120 Trametinib
0.031623
MEK
MAPK/nRTK
 0.5000 0.03555
CAL-120 Trametinib
0.1
MEK
MAPK/nRTK
 0.4765 0.06595